NKTR

Nektar Therapeutics

74.14 USD

Last updated Sep 5, 10:50 UTC

Yesterday HIGH

$75.63

Yesterday LOW

$73.66

52w HIGH

$109

52w LOW

$27.87

EPS

-1.23

PE

-60.28

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Nektar Therapeutics stock is up 0.94% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 32 September’s closed higher than August. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

25 Aug 13:37	21 Jan, 2028	65.00	CALL	53	358
25 Aug 13:49	16 Oct, 2026	90.00	CALL	400	6
25 Aug 15:18	18 Sep, 2026	85.00	CALL	140	1624
25 Aug 16:26	20 Nov, 2026	75.00	CALL	87	712
25 Aug 17:00	15 Jan, 2027	70.00	CALL	72	724
28 Aug 15:52	15 Jan, 2027	65.00	PUT	100	136
31 Aug 15:09	20 Nov, 2026	80.00	CALL	50	633
03 Sep 14:34	18 Sep, 2026	75.00	PUT	54	189
03 Sep 15:13	21 Jan, 2028	80.00	PUT	14	17
03 Sep 15:13	21 Jan, 2028	80.00	PUT	150	17

Advanced Data Unlock

Benzinga Newsdesk

Tue Apr 21, 2026

Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.
Benzinga Newsdesk

Mon Apr 20, 2026

Nektar Therapeutics Launches $250M Common Stock Offering

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public
Benzinga Newsdesk

Mon Apr 20, 2026

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185

HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.
Benzinga Newsdesk

Mon Apr 20, 2026

BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178

BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.
Avi Kapoor

Mon Apr 20, 2026

Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday

Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
Dylan Berman

Mon Apr 20, 2026

Why Are Nektar Shares Up Monday?

Nektar Therapeutics shares are trading higher Monday after a blinded 16-week treatment extension results in Phase 2b REZOLVE-AA study.
Benzinga Newsdesk

Mon Apr 20, 2026

Nektar Therapeutics shares are trading higher after the company announced results from a blinded 16-week treatment extension period in its Phase 2b REZOLVE-AA study.
Benzinga Newsdesk

Mon Apr 20, 2026

Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Mon Apr 20, 2026

Nektar Therapeutics Announces Its Phase 2b REZOLVE-AA Trial Evaluating Rezpegaldesleukin Demonstrates 29% And 31% Of Participants In Two Different Doses Extension Achieves New Severity Of Alopecia Tool Score Of Less Than Or Equal To 20

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced new results from a blinded 16-week treatment extension period in its
Benzinga Newsdesk

Mon Apr 20, 2026

Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending

JP Morgan

Fri Aug 21, 21:02

hold

confirm

Advanced Data Unlock

Jonathan Zalevsky, Chief R&D Officer

Tue Aug 18, 2026

NKTR Recent Insider Trades and Stock Chart

186 shares sold
HOWARD ROBIN, President & CEO

Tue Aug 18, 2026

NKTR Recent Insider Trades and Stock Chart

418 shares sold